✦ LIBER ✦

Significance of serum osteoprotegerin and receptor activator of nuclear factor κB ligand in Japanese prostate cancer patients with bone metastasis

✍ Scribed by Naoto Kamiya; Hiroyoshi Suzuki; Takumi Endo; Makoto Takano; Masashi Yano; Makito Naoi; Koji Kawamura; Takashi Imamoto; Masaharu Takanami; Tomohiko Ichikawa

Publisher: Springer
Year: 2011
Tongue: English
Weight: 197 KB
Volume: 16
Category: Article
ISSN: 1341-9625
DOI: 10.1007/s10147-011-0193-7

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Role of receptor activator of nuclear fa

Role of receptor activator of nuclear factor-κB ligand and osteoprotegerin in bone cell biology

✍ Lorenz C. Hofbauer; Armin E. Heufelder 📂 Article 📅 2001 🏛 Springer 🌐 English ⚖ 119 KB

Plasma levels of receptor activator of n

Plasma levels of receptor activator of nuclear factor-κB ligand and osteoprotegerin in patients with neuroblastoma

✍ Donatella Granchi; Alberto Garaventa; Ilaria Amato; Paolo Paolucci; Nicola Baldi 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 French ⚖ 141 KB

## Abstract Earlier reports showed that the balance between receptor activator of nuclear factor‐κB ligand (RANKL) and its decoy‐receptor osteoprotegerin (OPG) plays an important role in the pathogenesis of metastatic osteolysis induced by neuroblastoma cells. In this study, we investigated whether

Expression of receptor activator of nucl

Expression of receptor activator of nuclear factor -κB ligand, receptor activator of nuclear factor -κB, and osteoprotegerin, following low-level laser treatment on deproteinized bovine bone graft in rats

✍ Yong-Deok Kim; Won-Wook Song; Seong-Sik Kim; Gyu-Cheon Kim; Dae-Seok Hwang; Sang 📂 Article 📅 2008 🏛 Springer-Verlag 🌐 English ⚖ 574 KB

Serum osteoprotegerin and receptor activ

Serum osteoprotegerin and receptor activator of nuclear factor-κB ligand (RANKL) concentrations in allogeneic stem cell transplant-recipients: a role in bone loss?

✍ K. Kananen; L. Volin; K. Laitinen; T. Ruutu; M. J. Välimäki 📂 Article 📅 2005 🏛 Springer-Verlag 🌐 English ⚖ 136 KB

Effects of disease-modifying antirheumat

Effects of disease-modifying antirheumatic drugs and antiinflammatory cytokines on human osteoclastogenesis through interaction with receptor activator of nuclear factor κB, osteoprotegerin, and receptor activator of nuclear factor κB ligand

✍ Chang-Keun Lee; Eun Young Lee; Son Mi Chung; Se Hwan Mun; Bin Yoo; Hee-Bom Moon 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 649 KB

## Abstract ## Objective To demonstrate the effects of disease‐modifying antirheumatic drugs and antiinflammatory cytokines on human osteoclastogenesis through their effects on receptor activator of nuclear factor κB (RANK), osteoprotegerin (OPG), and RANK ligand (RANKL). ## Methods Peripheral b

Receptor activator of nuclear factor-κB

Receptor activator of nuclear factor-κB ligand and osteoprotegerin : Potential implications for the pathogenesis and treatment of malignant bone diseases

✍ Lorenz C. Hofbauer; Andreas Neubauer; Armin E. Heufelder 📂 Article 📅 2001 🏛 John Wiley and Sons 🌐 English ⚖ 142 KB 👁 1 views

## Background: The current review summarizes the roles of the ligand, receptor activator of nuclear factor-kappab ligand (rankl), its receptor, receptor activator of nuclear factor-kappab (rank), and its decoy receptor, osteoprotegerin (opg), on osteoclast biology and bone resorption. furthermore,